NEXT SCIENCE LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.42 AUD | -1.18% |
|
+10.53% | +23.53% |
Presenter SpeechMark Compton (Executives)Well, good morning, everyone, and good morning to tho...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Next Science Limited is an Australia-based medical technology company. The Companyâs primary focus is on the development and commercialization of its proprietary XBIO technology to reduce the impact of biofilm-based infections on human health. XBIO is a non-toxic technology with an efficacy in eradicating both biofilm-based and free-floating bacteria. The Companyâs products include XPERIENCE, Blast X, SurgX and Bactisure. The XPERIENCE product is an antimicrobial solution used to prevent surgical site infections by rinsing away debris and microorganisms. SurgX Sterile Antimicrobial Gel is used to reduce surgical site and post-surgical infections by destroying planktonic and biofilm-based bacteria within the gel with sustained effectiveness for up to five days. BLASTX Antimicrobial Wound Gel provides wound management by maintaining a moist wound environment, which is conducive to wound healing.
Sector
Pharmaceuticals
Calendar
2024-04-23
- March 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.2722
USD
Average target price
0.2415
USD
Spread / Average Target
-11.27%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +23.53% | 79.79M | |
| +27.92% | 659B | |
| +27.68% | 557B | |
| -4.59% | 359B | |
| +16.38% | 322B | |
| +9.39% | 297B | |
| +6.30% | 215B | |
| +4.80% | 210B | |
| -6.05% | 200B | |
| -8.58% | 149B |
- Stock Market
- Equities
- NXS Stock
- News Next Science Limited
- Transcript : Next Science Limited - Shareholder/Analyst Call
